



92(24.3%) with 95% CI: 20.1%–29% and 15(3.97%) with 95% CI: 2.2%–6.5% respectively. Of the VRSA isolates, 11(91.7%) were susceptible to tigecycline. Forty (43.5%) of *S. aureus* were positive for inducible clindamycin resistance. Participants with a history of hospitalization at the intensive care unit were 37 times more likely to be colonized with VRSA ( $p=0.001$ ). Participants who have domestic animals were 22 times more likely to be colonized with VRSA ( $p=0.021$ ).

**Conclusions:** This study indicated a high proportion of VRSA and VISA among *S. aureus* isolated from hospitalized patients in the study area. More than 80% of VRSA were susceptible to tigecycline. History of hospitalization at the intensive care unit and having domestic animals at home could increase the odds of VRSA colonization.

**Keywords:** Nasal Carriage Rate, Vancomycin resistant *Staphylococcus aureus*, Methicillin resistant *S. aureus*, Admitted patients, Sidama, Ethiopia

## Background

Antimicrobial resistance (AMR) is one of the most important public health problems in the world disproportionately affecting low-income countries (1). Worldwide dissemination of drug-resistant bacteria with few developments of antimicrobial agents is a formidable challenge that the physicians of today are facing (1).

*Staphylococcus aureus* is among potential pathogenic bacteria with diverse virulence factors and the potential to develop resistance to commonly used antimicrobial agents. *S. aureus* are colonizer of the skin and upper respiratory tract without causing diseases. If there are underlying conditions it can cause community and hospital-acquired infections such as soft tissue infections, bacteremia, endocarditis, pneumonia, meningitis, and osteomyelitis (2).

*S. aureus* is a frequent inhabitant of the human upper respiratory tract and the skin (3); however, the carriage rate varies based on geographic location, age, gender, and ethnicity (4). The nasal carriage of *S. aureus* has been identified as a risk factor for community-acquired and nosocomial infections (5).

*S. aureus* has developed resistance to penicillin and methicillin over time, which makes infection caused by *S. aureus* difficult to treat (6). Vancomycin, a glycopeptide antibiotic, has been used as a last-line antibiotic for treating life-threatening infections caused by Methicillin-resistant *S. aureus* (MRSA) (7). This option is being challenged by the emergence

64 and spread of *S. aureus* which are completely resistant to vancomycin or reduced  
65 susceptibility to vancomycin (7, 8).

66 *S. aureus* strains exhibiting reduced susceptibility to vancomycin, vancomycin intermediate-  
67 resistant *S. aureus* (VISA), were discovered in the 1990s. *S. aureus* isolates with complete  
68 resistance to vancomycin, vancomycin-resistant *S. aureus* (VRSA), was first reported in the  
69 United States in 2002. The burden of VISA is higher than VRSA; it is associated with  
70 persistent infections, vancomycin treatment failure, and poor clinical outcomes (7, 8). VRSA  
71 was among the list of antibiotic-resistant microorganisms identified by the World Health  
72 Organization (WHO) in 2017 for which new antibiotics should be developed (9).  
73 Furthermore, VRSA remained in the 2019 WHO updated list as a high-priority pathogen  
74 (10).

75 Infections caused by VRSA have been associated with high morbidity and mortality rates due  
76 to the limited availability of effective drugs, particularly in low-income countries. In  
77 Ethiopia, the prevalence of drug-resistant bacteria has been increasing from time to time (11).  
78 The prevalence of VRSA reported from other parts of Ethiopia (12, 14) is mostly based on  
79 the disc diffusion method. Some studies from Ethiopia used E-test and Micro-dilution  
80 methods for the determination of VRSA (15, 16). In addition to searching for alternative  
81 treatments for infection caused by VRSA, it is important to monitor the epidemiology of  
82 VRSA. Considering the scarcity of data in the southern parts of Ethiopia and the disparity in  
83 methods used for the detection of VRSA, we primarily envisaged determining the nasal  
84 carriage rate of VRSA among admitted patients, its predictors, and antimicrobial  
85 susceptibility profile. We also determined the proportion of VISA, MRSA, and ICR *S.*  
86 *aureus*.

## 87 **Methods**


### 88 **Study design and study population**

89 A hospital-based prospective cross-sectional study was conducted among patients admitted to  
90 Hawassa University Comprehensive Specialized Hospital (HUCSH) from April to June 2023.  
91 The hospital is located in Hawassa city, which is the capital city of Sidama regional state,  
92 Ethiopia. HUCSH is a referral hospital that provides health-related services for people  
93 coming from the Sidama regional state and other neighboring regional states. It has 284  
94 functional beds and 12 wards such as surgical ward, medical ward, ophthalmology ward,

neurology ward, gynecology ward, orthopedics ward, pediatrics ward, pedi-surgery ward, oncology ward, adult and neonatal intensive care units, and trauma ward. We have included six wards for the present study based on the patient flow.

In this study, we included patients who were admitted to the HUCSH during the study period for treatment. Patients who were critically sick and had nasal bleeding were excluded from the study. The sample size was determined based on a single sample size estimation formula. We have considered the prevalence of VRSA (4.1%) which was reported from Debre Markos, Ethiopia (17). By assuming a 5% for non-response rate, the sample size was 378.

A total of 2,222 patients were admitted from September to December. The sample size was proportionally allocated to seven wards by multiplying,  $378/2222$  (0.17), with a number of patients admitted at each ward between September to December 2022 (Figure 1). A systematic random sampling technique was used to select study participants. The k-value was determined based on the total number of patients allocated to each ward. The first participant was selected using the lottery method.



109

110 **Figure 1.** Total number of patients admitted to selected wards of HUCSH from September to  
111 December 2022 and proportional allocation of participant at each ward.

112

## Data Collection

A structured questionnaire prepared on kobo-collect version 2023.1.2 (United States) was used to collect socio-demographic and clinical data. The questionnaire was prepared after reviewing similar published articles (5, 12, 13, 19). To ensure consistency, the questionnaire was first prepared in English, translated into Amharic, and then translated back into English. The data was collected using the Amharic version of the questionnaire. The questionnaire was pretested in a population representing 5% (n=19) of the sample size at Adare General Hospital, Hawassa, Ethiopia.

The anterior nostrils were swabbed aseptically using sterile cotton soaked in saline and placed in a tube containing normal saline. The swabs were inoculated onto mannitol salt agar (MSA) (Oxoid, Hampshire UK) and incubated at 37°C for 24 hours in an aerobic environment. After 24 hours of incubation, MSA plates were inspected for visible growth of bacteria. In cases where there was no visible growth of bacteria, plates were re-incubated for an additional 24 hours. For bacterial growth with yellow colonies on MSA, Gram staining was performed. Gram-positive cocci bacteria in a cluster on microscopic examination were tested using catalase, coagulase, and modified oxidase test. Bacteria were considered as *S. aureus* if it appeared yellow on MSA, catalase positive, coagulase-positive and modified oxidase test negative. We used a modified oxidase test to differentiate *S. aureus* from *Micrococcus* which may appear yellow on MSA and can wrongly be considered as *S. aureus*. Confirmed *S. aureus* isolates were tested for VRSA, MRSA, and antimicrobial susceptibility testing. Before use, the sterility of all culture media used in this study was checked by incubating 5% of each batch of the culture media without inoculation. For performance testing of Gram staining, culture media, biochemical tests, and antibiotics reference strains were used.

## Detection of vancomycin resistant *S. aureus*

The pure isolate of *S. aureus* was suspended in a phosphate buffer solution until it matched the McFarland 0.5 standard. The suspension was inoculated over the surface of Muller Hinton Agar (MHA) uniformly using a sterile cotton swab dipped into a suspension. Vancomycin E-test (bioMérieux SA, Marcy-l'Étoile, France) was applied to MHA in which *S. aureus* was inoculated and incubated for 24 hours aerobically at 37°C. The reading was interpreted according to Clinical Laboratory Standard Institute (CLSI) guidelines as susceptible, intermediate, and resistant (18). Minimum inhibitory concentrations of  $\leq 2$  µg/ml,

4–8µg/ml, and ≥16µg/ml were interpreted as susceptible (S), intermediate (I), and resistant (R) respectively.

To detect MRSA, *S. aureus* suspension was prepared and inoculated onto MHA as mentioned above; a cefoxitin (30µg) antibiotic was applied and incubated for 18 hours in ambient air at 35°C. Zone of inhibition <21 mm was interpreted as MRSA. Inducible clindamycin resistance (ICR) was identified using a D-test which involves the application of erythromycin (E-15 µg) and clindamycin (CD-2 µg) discs spaced 15–26 mm on MHA as per CLSI guidelines (18). Flattening of the zone of inhibition adjacent to the erythromycin disc and cloudy growth within the zone of inhibition around clindamycin indicates ICR.

### Antibiotic susceptibility testing

The disc diffusion method was used to determine the antibiotic susceptibility profile of *S. aureus* as described in CLSI guidelines (18). The suspension of *S. aureus* was prepared and inoculated onto MHA as described above. The antibiotics used for disc diffusion assays include cefoxitin (30µg), erythromycin (15µg), trimethoprim-sulfamethoxazole (1.25/23.7, 5µg), ciprofloxacin (5µg), chloramphenicol (30µg), gentamicin (10µg), clindamycin (2µg), azithromycin (15µg), tigecycline (15µg), aztreonam (30µg), doxycycline (30µg), penicillin G (10 unit). MHA was incubated at 35–37°C for 24 hours. The zones of inhibition were measured using a caliper, and interpreted as susceptible (S), intermediate (I), or resistant (R).

### Data Analysis and Interpretation

Data was cleaned, transformed, coded, and analyzed using SPSS version 22. Data was presented in frequency and percent. The association between independent and dependent variables was determined using the binary logistic regression model; variables with  $p \leq 0.25$  in bivariate analysis were included in the multivariable logistic regression model to identify variables that predict VRSA colonization. All independent variables with a  $p \leq 0.05$  were considered statistically significant.

## Results

### Socio demographic and clinical characteristics

A total of 378 admitted patients at HUCSH were included in the study with a 100% response rate. The majority (n=215; 56.9%) of the study participants were males. The mean age of study participants was 44.5 with a standard deviation (SD) of 19.2 years. Most of the study participants (n=160; 42.3%) were from Sidama Regional State. More than half of the

176 participants were on IV or catheter while 126 (33.3%) reported repeated use of antibiotics  
177 (Table 1).

178 **Table 1.** Socio-demographic and clinical characteristics of admitted patients at Hawassa  
179 HUCSH, Hawassa, Ethiopia, April to June 2023 (N=378).

Characteristics	Category	Frequency (%)
Gender	Male	215 (56.9)
	Female	163 (43.1)
Region	Oromia	157 (41.5)
	Sidama	160 (42.3)
	SNNPRS	49 (13)
	Amhara	9 (2.4)
	Addis Ababa	1 (0.3)
	Somali	2 (0.5)
Place of residence	Urban	200 (52.9)
	Rural	178 (47.1)
Occupation	Self-employed	265 (70.1)
	Government	
	Employee	37 (9.8)
	House-wife	70 (18.5)
Educational status	Other employment	6 (1.6)
	No formal education	131 (34.7)
	1–8	168 (44.4)
	9–12	54 (14.3)
Marital status	>12	25 (6.6)
	Married	189 (50)
	Single	102 (27)
	Divorced	58 (15.3)
Admitted Ward	Widowed	29 (7.7)
	Oncology	123 (32.5)
	Ophthalmology	79 (20.9)
	Surgical	60 (15.9)
	Orthopedics	52 (13.8)
	Medical	40 (10.6)
Recurrent wound	Neurology	24 (6.3)
	Yes	111 (29.4)
Current nasal infection/itching	No	267 (70.6)
	Yes	132 (34.9)
History of hospitalization in the last six months	No	246 (65.1)
	Yes	169 (44.7)
Repeated use of antibiotics	No	209 (55.3)
	Yes	126 (33.3)
Use of antibiotics with physician prescription	No	252 (66.7)
	Yes	65 (17.7)
History of ICU hospitalization	No	61 (16.2)
	Yes	67 (17.7)



	No	311 (82.3)
	Yes	93 (24.6)
Prescience of co-morbidity	No	285 (75.4)
	Yes	229 (60.6)
IV/Catheter in the body	No	149 (39.4)
	Yes	216 (57.1)
Regular hand washing	No	162 (42.9)
	Yes	202 (53.4)
Repeated use of public toilet	No	176 (46.6)
	Yes	214 (56.6)
Domestic animal at home	No	164 (43.4)

180 SNNPRS: South nation nationalities and peoples regional state, ICU: Intensive care unit, IV: Intravenous  
181 Others option in occupation section includes; the church/mosque leaders

## 182 **Prevalence of *S. aureus*, VRSA, and MRSA**

183 Out of the total *S. aureus* isolated, 12(13.04%) 95% CI: 6.9%–21.7% and 27(29.3%) 95% CI;  
184 20.3%–39.8% were VRSA and VISA. 15(16.3%) 95% CI: 9.4%-25.5% of *S. aureus* were  
185 MRSA. Out of 15 MRSA, 3 were vancomycin resistant. Out of the total *S. aureus* isolated,  
186 21 (22.83%) were susceptible to both erythromycin and clindamycin whereas 31(33.7%)  
187 were resistant to both erythromycin and clindamycin indicating constitutive resistance  
188 (cMLSB). Forty (43.5%) of *S. aureus* were resistant to erythromycin and susceptible to  
189 clindamycin indicating ICR (iMLSB). The prevalence of VRSA, VISA, MRSA, and overall  
190 *S. aureus* colonization rate among admitted patients were 12(3.2%) 95% CI: 1.7%–5.5%,  
191 27(7.14%) 95%CI: 4.8%–10.2%, 15(3.97%) 95%CI: 2.2%–6.5%, and 92(24.3%) 95% CI:  
192 20.1%–29% respectively.



# **Factors associated with VRSA**

In bivariate logistic regression analysis, recurrent wound ( $p=0.04$ ,  $COR=3.69(95\% CI:1.06-12.9)$ ), nasal infection ( $p=0.024$ ,  $COR=4.4(95\% CI:1.21-15.9)$ ), history of hospitalization ( $p=0.033$ ,  $COR=4.5(95\% CI: 1.13-17.9)$ ), repeated use of antibiotics ( $p=0.04$ ,  $COR=3.93(95\% CI:1.08-14.2)$ ), history of hospitalization at ICU ( $p<0.0001$ ,  $COR= 31.4(95\% CI:6.05-162.7)$ ) and having domestic animal at home ( $p=0.019$ ,  $COR=12.16(95\% CI: 1.49-98.6)$ ) were significantly associated with VRSA colonization. Variables with  $p< 0.25$  in the bivariate logistic regression model were included in multivariable logistic analysis. History of hospitalization at ICU ( $p=0.001$ ,  $AOR=37.2(95\% CI: 4.32-320.8)$ ) and having a domestic animal at home ( $p=0.021$ ,  $AOR=22.37(95\% CI: 1.59-313.1)$ ) were significantly associated with VRSA colonization in multivariable logistic regression analysis (Table 2).

206

207 **Table 2.** Factors associated with VRSA carriage among patients admitted at HUCSH, Hawassa, Ethiopia, April to June 2023 (N=92).

Variables		Frequency (%)	VRSA		COR(95% CI)	P-value	AOR (95% CI)	P-value
			Positive n (%)	Negative n(%)				
Sex	Male	66 (71.7)	9 (13.6)	57 (86.4)	1.21(0.30-4.87)	0.78		
	Female	26 (28.3)	3 (11.5)	23 (88.5)	1			
Place of residence	Rural	42 (45.7)	5 (11.9)	37 (88.1)	0.83(0.24-2.84)	0.77		
	Urban	50 (54.3)	7 (14)	43 (86)	1			
Educational status	No formal education	30 (32.6)	5 (16.7)	25 (83.3)	1.2(0.12-12.3)	0.88		
	1-8	45 (48.9)	5 (11.2)	40 (88.8)	0.75(0.074-7.57)	0.81		
	9-12	10 (10.9)	1 (10)	9 (90)	0.67(0.035-12.8)	0.78		
	>12	7(7.6)	1 (14.3)	6 (85.7)	1			
Marital status	Married	49 (53.3)	6 (12.2)	43 (87.8)	0.28(0.064-1.2)	0.089		
	Single	23 (25)	1 (4.3)	22 (95.7)	0.09(0.009-0.94)	0.044		
	Widowed	8 (8.7)	1 (12.5)	7 (87.5)	0.28(0.026-3.19)	0.286		
	Divorced	12 (13)	4 (33.3)	8 (66.7)	1			
Ward	Oncology	22 (23.9)	7 (31.8)	15 (68.2)	1			
	Ophthalmology	25 (27.2)	2 (8)	23 (92)	0.186(0.03-1.02)	0.053		
	Surgical	10 (10.9)	2 (20)	8 (80)	0.54(0.09-3.21)	0.49		
	Orthopedics	18 (19.6)	1 (5.6)	17 (94.4)	0.13(0.014-1.15)	0.06		
	Medical	12 (13)	-	12 (100)		0.99		
	Neurology	5 (5.4)	-	5 (100)		0.99		
Recurrent wound	Yes	29 (31.5)	7 (24.1)	22 (75.9)	3.69(1.06-12.9)	0.04	1.98(0.27-14.2)	0.49
	No	63 (68.5)	5 (7.9)	58 (92.1)	1		1	
Current nasal infection/itching	Yes	33 (35.9)	8 (24.2)	25 (75.8)	4.4(1.21-15.9)	0.024	0.84(0.08-8.1)	0.884
	No	59 (64.1)	4 (6.8)	55 (93.2)	1		1	
History of Hospitalization in the last 6-month	Yes	41 (44.6)	9 (21.9)	32 (78.1)	4.5(1.13-17.9)	0.033	1.31(0.18-9.48)	0.78
	No	51 (55.4)	3 (5.8)	48 (94.2)	1		1	

Repeated use of Antibiotics	Yes	35 (38)	8 (22.9)	27 (77.1)	3.93(1.08-14.2)	0.04	0.99(0.096-10.26)	0.995
	No	57 (62)	4 (7)	53 (93)	1		1	
Use of antibiotics with physician's prescription	Yes	26 (74.3)	5 (19.2)	21 (80.8)	1			
	No	9 (25.7)	3 (33.3)	6 (66.7)	2.1(0.38-11.4)	0.39		
History of ICU Hospitalization	Yes	21 (22.8)	10 (47.6)	11 (52.4)	31.4(6.05-162.7)	0.00004	37.2(4.32-320.8)**	0.001
	No	71 (77.2)	2 (2.8)	69 (97.2)	1		1	
Prescience of any co-morbidity	Yes	20 (21.7)	4 (20)	16 (80)	2(0.53-7.48)	0.30		
	No	72 (78.3)	8 (11.1)	64 (88.9)	1			
IV/Catheter in the body	Yes	57 (62)	9 (15.8)	48 (84.2)	2(0.5-7.96)	0.32		
	No	35 (38)	3 (8.6)	32 (91.4)	1			
Regular hand washing	Yes	56 (60.9)	8 (14.3)	48 (85.7)	1.33(0.37-4.8)	0.66		
	No	36 (39.1)	4 (11.1)	32 (88.9)	1			
Repeated use of public toilet	Yes	58 (63)	9 (15.5)	49 (84.5)	1.89(0.47-7.56)	0.36		
	No	34 (37)	3 (8.8)	31 (91.2)	1			
Domestic animal in home	Yes	49 (53.3)	11 (22.4)	38(77.6)	12.16(1.49-98.6)	0.019	22.37(1.59-313.1)*	0.021
	No	43 (46.7)	1 (2.3)	42 (97.7)	1		1	

VRSA: vancomycin resistant *S. aureus*, CI: Confidence interval, OR: Odds ratio, AOR: Adjusted odds ratio, ICU: Intensive care unit, AOR: Adjusted odds ratio, ICU: Intensive care unit, COR: Crude odd ratio, AOR: Adjusted odd ratio

In bivariate analysis gender ( $p=0.001$ , COR=2.3 (95% CI:1.38–3.8)), repeated use of antibiotics with physician's prescription ( $p=0.002$ , COR=0.26(95% CI:0.11–0.62)), and repeated use of public toilet ( $p=0.035$ , COR=1.68(95% CI:1.04–2.73)) were significantly associated with overall *S. aureus* colonization rate while in multivariable analysis gender ( $p=0.008$ , AOR=3.67(95% CI:1.4–9.6)), repeated use of antibiotics with physician's prescription ( $p= 0.009$ , AOR=0.28(95% CI: 0.11–0.73)) and history of hospitalization at ICU ( $p=0.023$ , AOR=3.34(95% CI: 1.2–9.46)) were significantly associated with overall *S. aureus* colonization rate (Supplement table 1).

In bivariate logistic analysis, history of ICU hospitalization ( $p = 0.004$ , COR = 5.63(95% CI: 1.73–18.2)) showed significant association while in multivariate analysis, gender ( $p = 0.018$ , AOR = 0.16(95% CI: 0.035–0.73)) and history of ICU hospitalization ( $p = 0.008$ , AOR = 8.06(95% CI: 1.72–37.6)) were significantly associated with MRSA colonization (Supplement table 2).

### Antimicrobial susceptibility profile of VRSA

Out of the total *S. aureus* tested, 92(100%), 76(82.6%), 68(73.9%), and 66(71.7%) were resistant to aztreonam, penicillin G, sulfamethoxazole-trimethoprim (SXT), and azithromycin respectively on the other hand 88(95.7%), 82(89.1%), 77(83.7%) and 71(77.2%) of *S. aureus* were susceptible to tigecycline, doxycycline, cefoxitin, and chloramphenicol respectively (Table 3).


Out of the total VRSA, 12(100%), 11(91.7%), 9(75%), and 7(58.3%) were resistant to aztreonam, azithromycin, clindamycin, and gentamicin respectively while 11(91.75%), 10(83.3%), 9(75%), and 7(58.3%) VRSA were susceptible to tigecycline, doxycycline, cefoxitin, and gentamicin respectively (Table 3). A high proportion of vancomycin susceptible *S. aureus* was positive for inducible clindamycin resistance while the lowest inducible clindamycin resistance was observed among VRSA (Fig 2).

**Table 3.** Antimicrobial susceptibility profile of *S. aureus* and VRSA recovered from patients admitted at HUCSH, Hawassa, Ethiopia. April to June 2023.

Antimicrobials	<i>S. aureus</i> n=92			VRSA n=12		
	S, n (%)	I, n (%)	R, n (%)	S, n (%)	I, n (%)	R, n (%)
AZM	23 (25)	3 (3.3)	66 (71.7)	1 (8.3)	0	11 (91.7)
CD	68 (73.9)	1 (1.1)	23 (25)	5 (41.7)	0	7 (58.3)
TGC	88 (95.7)	NR	4 (4.3)	11 (91.75)	NR	1 (8.3)
AZT	0	0	92 (100)	0	0	12 (100)

CN	56 (60.9)	1 (1.1)	35 (38)	7 (58.3)	1 (8.3)	4 (33.3)
CIP	47 (51.1)	12 (13)	33 (35.9)	6 (50)	3 (25)	3 (25)
ERY	21 (22.8)	7 (7.6)	64 (69.6)	1 (8.3)	2 (16.7)	9 (75)
DOX	82 (89.1)	4 (4.3)	6 (6.5)	10 (83.3)	1 (8.3)	1 (8.3)
C	71 (77.2)	15 (16.3)	6 (6.5)	6 (50)	3 (25)	3 (25)
PEN G	16 (17.4)	NR	76 (82.6)	6 (50)	NR	6 (50)
SXT	24 (26.1)	0	68 (73.9)	1 (8.3)	0	11 (91.7)
FOX	77 (83.7)	NR	15 (16.3)	9 (75)	NR	3 (25)

239 VRSA: Vancomycin resistant *S. aureus*, S: Susceptible, I: Intermediate, R: Resistant, AZM: Azithromycin, CD:  
 240 Clindamycin, TGC: Tigecycline, AZT: Aztreonam, CN: Gentamicin, CIP: Ciprofloxacin, ERY: Erythromycin, DOX:  
 241 Doxycycline, C: Chloramphenicol,, PEN G: Penicillin G, SXT:- Sulfamethoxazole- trimethoprim , FOX: Cefoxitin,  
 242 NR: Not recommended by CLSI



243  
 244 **Figure 2.** Clindamycin resistance observed across *S. aureus*, VRSA and MRSA isolated from  
 245 admitted patients at HUCSH, Hawassa, Ethiopia April 05 to June 24 2023  
 246 VSSA: Vancomycin susceptible *S. aureus* VISA: Vancomycin intermediate *S. aureus*, VRSA: Vancomycin resistant *S. aureus*, S-ERY-CD:  
 247 Susceptible to both Erythromycin and clindamycin, cMLSB: constitutive resistance (Resistance to both Erythromycin and Clindamycin),  
 248 iMLS : inducible resistance to clindamycin, MRSA: Methicillin resistant *S. aureus*, MSSA: Methicillin susceptible *S. aureus*

## 249 Discussion

250 Infections caused by VRSA are public health concerns that require attention from  
 251 international and national health sectors. Treatment options for VRSA infections are limited.  
 252 Assessing the epidemiology of VRSA will provide valuable insights to help combat its spread  
 253 within the community. So far, a few studies in Ethiopia have identified VRSA using the  
 254 minimum inhibitory concentration method.

255 The present study found the proportion of VRSA among *S. aureus* isolates to be 13.04%.  
 256 This is consistent with studies conducted in Eritrea (15.9%) (19), Pakistan (11-15%) (20),

Egypt (13.8%) (21), Ethiopia (14-15%) (6, 16, 17, 22), and Indonesia (11%) (23). However, the VRSA prevalence in this study was higher than many other studies in Addis Ababa, Ethiopia (4-7%) (14, 15, 24), the global pooled estimate (6%) (25), Yemen (5.12%) (26), and Egypt (4.5%) (27). Conversely, studies from Nigeria (44.5%) (3), Bangladesh (27.6%) (26), and Egypt (24%) (29) reported a higher VRSA prevalence than the current study. The lowest VRSA rate (4.1%) in Ethiopia was reported from Jigjiga (14).

These variations could be attributed to differences in the study population, specimen collection site, laboratory method, study period, and antibiotic usage practices. The current study did not determine the origin of VRSA in the patients, who were admitted for various medical conditions. VRSA could have been acquired in the community before admission or during hospitalization. Further investigation using molecular epidemiology is needed to elucidate the source of VRSA in these patients.

The study found that participants with a history of ICU hospitalization were more likely to be colonized with VRSA ( $p=0.001$ ). Similar findings have been reported in previous studies by Wu et al. (25) and Shariati et al. (30). This could be attributed to the misuse of antimicrobial agents and the use of contaminated medical devices in hospital settings during patient management. Additionally, participants who had domestic animals at home were also more likely to be colonized with VRSA compared to those without domestic animals. This observation aligns with findings from other studies conducted in Ethiopia (17, 31). This may suggest that domestic animals could be a potential source of VRSA; however, the current study was not designed to definitively determine the source of VRSA infection.

The study found that all VRSA isolates were resistant to aztreonam, which is consistent with findings from a study conducted in Hyderabad (32). Additionally, over 25% of the isolates were resistant to azithromycin and sulfamethoxazole-trimethoprim, which is lower than the resistance rates reported in a study from Egypt (21). Conversely, only one isolate was resistant to tigecycline, a similar observation to a study in Pakistan (20).

The nasal carriage rate of *S. aureus* has been extensively studied, and various colonization rates have been reported across different regions and study populations (13, 33, 34, 43). The overall nasal carriage rate of *S. aureus* (24.3%) found in the present study is comparable to rates reported from Ethiopia (28.8%) (13), China (24.7%) (33), and Iran (21.3%) (43). However, it is lower than the rates observed in studies conducted in Iraq (39.4%) (34) and

other parts of Ethiopia (32%-39%) (16, 35). Notably, the nasal carriage rate in this study was higher than rates reported in other regions of Ethiopia (13%-16%) (36, 37).

These variations in the nasal carriage of *S. aureus* across different regions of Ethiopia suggest the existence of other factors that may contribute to different levels of colonization rates. The differences in the isolation rates of *S. aureus* among studies could be attributed to variations in clinical characteristics, study settings, socio-demographic factors, and individual behaviors.

The study found that male participants were 3.67 times more likely to be colonized with *S. aureus*, which contradicts the findings of other studies conducted in Jimma, Ethiopia (38). This discrepancy could be attributed to behavioral differences between males and females residing in various geographic locations within Ethiopia. Interestingly, study participants who did not use antibiotics without a physician's prescription were 72% less likely to be colonized with *S. aureus*. Additionally, participants with a history of ICU hospitalization were 3.34 times more likely to be colonized with *S. aureus*, a finding that aligns with the report by Humphreys et al. (39).

Among the 92 *S. aureus* isolates in the current study, 16.3% were resistant to cefoxitin, which is lower than the resistance rate reported in a study from Nigeria (40). However, 69.6% and 25% of the *S. aureus* isolates were resistant to erythromycin and clindamycin, respectively, which is lower than the resistance rates observed in a study conducted in Iran (41).

The magnitude of MRSA detected in the current study (16.3%) is consistent with reports from various parts of the world (11.2%-17.3%) (12, 15, 36, 43). However, it is lower than the MRSA rates reported in studies from Pakistan (76%) (44), Iran (74.2%) (45), Yemen (65%) (26), different regions of Ethiopia (30%-45%) (16, 17, 35, 46), Sudan (41%) (47), and Nepal (31.2%) (48).

Interestingly, male participants were about 84% less likely to be colonized with MRSA, which aligns with findings from other parts of Ethiopia (17, 39). Similar to the patterns observed for *S. aureus* and VRSA colonization, participants with a history of ICU hospitalization were about 8 times more likely to be colonized with MRSA compared to those without such a history.



## Limitation of the study

The present study did not employ the broth dilution method for the determination of VRSA. As a result, this work should be interpreted while considering the inherent limitations associated with the use of the E-test technique for VRSA detection.

## Conclusions

The study found that the proportion of vancomycin-resistant and vancomycin-intermediate *Staphylococcus aureus* (VRSA and VISA) was relatively high in the study area. Importantly, a history of hospitalization in the Intensive Care Unit (ICU) and having domestic animals at home were significantly associated with VRSA colonization. Further analysis revealed that most of the VRSA isolates were resistant to aztreonam, azithromycin, clindamycin, and gentamicin. In contrast, more than 80% of the VRSA isolates were susceptible to tigecycline and doxycycline.

## Abbreviations

VRSA: Vancomycin-resistant *S. aureus*, VISA: Vancomycin intermediate *S. aureus*, HUCSH: Hawassa University Comprehensive Specialized Hospital, E-test: Epsilometer test, MRSA: Methicillin resistant *S. aureus*, MHA: Muller Hinton Agar, CLSI: Clinical Laboratory Standard Institute, ICU: Intensive care unit

## Acknowledgments

We would like to acknowledge nurses and laboratory scientist working at selected wards of HUCSH and teaching Microbiology laboratory respectively. We also acknowledge study participants for their willingness to take part in the study.

## Declaration

## Ethical approval and consent to participate

Ethical approval was obtained from the institutional review board (IRB) of Hawassa University College of Medicine and Health Sciences with Ref No of IRB/171/15. Written informed consent was obtained from adults participants. For minors, both consent and assent was obtained. All methods were performed in accordance with the relevant guidelines and regulations.

## Funding

This study was partly supported by Hawassa University. The supporter does not have any role in designing and data collection.

# **Availability of data and materials**

The data set used can be obtained from corresponding author.

# **Authors' contributions**

**BKM:** Proposal development, laboratory work, data analysis, and drafting the original manuscript **TA:** supervision of the study, data analysis, and review of the manuscript **THM:** supervision of the laboratory work, and review of the manuscript **MMA:** proposed the study, supervision of laboratory work, data analysis and manuscript preparation

# **Consent for publication**

Not applicable

# **Competing interests**

The authors declare that they have no competing interests.

# **References**

1. Melese A, Genet C, Andualem T. Prevalence of Vancomycin resistant enterococci (VRE) in Ethiopia: a systematic review and meta-analysis. BMC infectious diseases. 2020 Dec; 20 (1):1-2.
2. Zheng X, Fang R, Wang C, Tian X, Lin J, Zeng W, *et al.* Resistance profiles and biological characteristics of rifampicin-resistant Staphylococcus aureus small-colony variants. Infection and Drug Resistance. 2021 Apr 21:1527-36.
3. Olufunmiso O, Tolulope I, Roger C. Multidrug and vancomycin resistance among clinical isolates of Staphylococcus aureus from different teaching hospitals in Nigeria. African health sciences. 2017 Sep 18; 17 (3):797-807.
4. Sollid JU, Furberg AS, Hanssen AM, Johannessen M. Staphylococcus aureus: determinants of human carriage. Infection, genetics and evolution. 2014 Jan 1; 21: 531-41.
5. Legese H, Kahsay AG, Kahsay A, Araya T, Adhanom G, Muthupandian S, *et al.* Nasal carriage, risk factors and antimicrobial susceptibility pattern of methicillin resistant Staphylococcus aureus among healthcare workers in Adigrat and Wukro

hospitals, Tigray, Northern Ethiopia. BMC research notes. 2018 Dec; 11 (1):1-6.

6. Belete MA, Gedefie A, Alemayehu E, Debash H, Mohammed O, Gebretsadik D, *et al.* The prevalence of vancomycin-resistant *Staphylococcus aureus* in Ethiopia: a systematic review and meta-analysis. Antimicrobial Resistance & Infection Control. 2023 Aug 30; 12 (1):86.
7. McGuinness WA, Malachowa N, DeLeo FR. Focus: infectious diseases: vancomycin resistance in *Staphylococcus aureus*. The Yale journal of biology and medicine. 2017 Jun; 90 (2):269.
8. Islam F, Shohag S, Uddin MJ, Islam MR, Nafady MH, Akter A. *et al.* Exploring the journey of zinc oxide nanoparticles (ZnO-NPs) toward biomedical applications. Materials. 2022 Mar 15; 15 (6):2160.
9. Tacconelli E, Magrini N, Kahlmeter G, Singh N. Global priority list of antibiotic-resistant bacteria to guide research. Discovery and Development of New Antibiotics. 2017:1-7.
10. World Health Organization. 2019 Antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO.
11. Berhe DF, Beyene GT, Seyoum B, Gebre M, Haile K, Tsegaye M, *et al.* Prevalence of antimicrobial resistance and its clinical implications in Ethiopia: a systematic review. Antimicrobial Resistance & Infection Control. 2021 Dec; 10:1-4.
12. Manilal A, Shewangizaw M, Mama M, Gezmu T, Merdekios B. Methicillin-resistant *Staphylococcus aureus* colonization in HIV patients of Arba Minch province, Ethiopia: carriage rates, antibiotic resistance, and biofilm formation. Acta microbiologica et immunologica Hungarica. 2019 Dec; 66(4):469-83.
13. Shibabaw A, Abebe T, Mihret A. Antimicrobial susceptibility pattern of nasal *Staphylococcus aureus* among Dessie Referral Hospital health care workers, Dessie, Northeast Ethiopia. International Journal of Infectious Diseases. 2014 Aug 1; 25: 22-5.
14. Abebe T, Teklemariam Z, Shume T, Mekuria S, Urgesa K, Weldegebreal F. Bacterial Profile of External Ocular Infections, Its Associated Factors, and Antimicrobial Susceptibility Pattern among Patients Attending Karamara Hospital, Jigjiga, Eastern Ethiopia. International Journal of Microbiology. 2023 Mar 10; 2023.
15. Dilnessa T, Bitew A. Prevalence and antimicrobial susceptibility pattern of methicillin resistant *Staphylococcus aureus* isolated from clinical samples at Yekatit 12 Hospital

Medical College, Addis Ababa, Ethiopia. BMC infectious diseases. 2016 Dec; 16: 1-9.

16. Kejela T, Dekosa F. High prevalence of MRSA and VRSA among inpatients of Mettu Karl Referral Hospital, Southwest Ethiopia. Tropical Medicine & International Health. 2022 Aug; 27(8):735-41.

17. Tefera S, Awoke T, Mekonnen D. Methicillin and vancomycin resistant *Staphylococcus aureus* and associated factors from surgical ward inpatients at Debre Markos Referral Hospital, Northwest Ethiopia. Infection and Drug Resistance. 2021 Aug 10:3053-62.

18. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. CLSI supplement M100. 2022 Jan 18:106-12.

19. Garoy EY, Gebreab YB, Achila OO, Tekeste DG, Kesete R, Ghirmay R, *et al.* Methicillin-resistant *Staphylococcus aureus* (MRSA): prevalence and antimicrobial sensitivity pattern among patients—a multicenter study in Asmara, Eritrea. Canadian Journal of Infectious Diseases and Medical Microbiology. 2019 Oct;2019.

20. Saeed A, Ahsan F, Nawaz M, Iqbal K, Rehman KU, Ijaz T. Incidence of vancomycin resistant phenotype of the methicillin resistant *Staphylococcus aureus* isolated from a tertiary care hospital in Lahore. Antibiotics. 2019 Dec 18;9(1):3.

21. ElSayed N, Ashour M, Amine AE. Vancomycin resistance among *Staphylococcus aureus* isolates in a rural setting, Egypt. Germs. 2018 Sep;8(3):134.

22. Deyno S, Fekadu S, Astatkie A. Resistance of *Staphylococcus aureus* to antimicrobial agents in Ethiopia: a meta-analysis. Antimicrobial Resistance & Infection Control. 2017 Dec;6(1):1-5.

23. Ahmad F, Sennang N, Rusli B. Vancomycin resistant *Staphylococcus aureus* in Dr. Wahidin Sudirohusodo Hospital Makassar. Indonesian Journal of Clinical Pathology and Medical Laboratory. 2019 Apr 13; 25 (2):194-8.

24. Alebachew T, Yismaw G, Derabe A, Sisay Z. *Staphylococcus aureus* burn wound infection among patients attending Yekatit 12 hospital burn unit, Addis Ababa, Ethiopia. Ethiopian journal of health sciences. 2012; 22(3).

25. Wu Q, Sabokroo N, Wang Y, Hashemian M, Karamollahi S, Kouhsari E. Systematic review and meta-analysis of the epidemiology of vancomycin-resistance *Staphylococcus aureus* isolates. Antimicrobial Resistance & Infection Control. 2021 Dec; 10: 1-3.

26. Abdelmonem MO. Nasal carriage of *Staphylococcus aureus* among healthcare

- workers in althawra hospital, Taiz city, Republic of Yemen. Australian Journal of Basic and Applied Sciences. 2012;6(7):417-24.
27. Shady AH, El-Essawy AK, Salama MS, El-Ayesh AM. Detection and molecular characterization of vancomycin resistant *Staphylococcus aureus* from clinical isolates. African Journal of Biotechnology. 2012; 11(99):16494-503.
28. Hasan R, Acharjee M, Noor R. Prevalence of vancomycin resistant *Staphylococcus aureus* (VRSA) in methicillin resistant *S. aureus* (MRSA) strains isolated from burn wound infections. Tzu Chi Medical Journal. 2016 Jun 1; 28(2):49-53.
29. Salah NM, Saafan AE, Salem EH, El Rabey HA, Alsieni MA, Alatawi Fa *et al.* Inhibition of the vancomycin resistance in *Staphylococcus aureus* in Egypt using silver nanoparticles. BioMed Research International. 2022 Apr 30;2022.
30. Shariati A, Dadashi M, Moghadam MT, van Belkum A, Yaslianifard S, Darban-Sarokhalil D. Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate *Staphylococcus aureus* clinical isolates: a systematic review and meta-analysis. Scientific reports. 2020 Jul 29;10(1):12689.
31. Beyene T, Hayishe H, Gizaw F, Beyi AF, Abunna F, Mammo B, Ayana D, *et al.* Prevalence and antimicrobial resistance profile of *Staphylococcus* in dairy farms, abattoir and humans in Addis Ababa, Ethiopia. BMC research notes. 2017 Dec; 10(1):1-9.
32. Thati V, Shivannavar CT, Gaddad SM. Vancomycin resistance among methicillin resistant *Staphylococcus aureus* isolates from intensive care units of tertiary care hospitals in Hyderabad. The Indian journal of medical research. 2011 Nov;134(5):704.
33. Chen BJ, Xie XY, Ni LJ, Dai XL, Lu Y, Wu XQ, *et al.* Factors associated with *Staphylococcus aureus* nasal carriage and molecular characteristics among the general population at a Medical College Campus in Guangzhou, South China. Annals of clinical microbiology and antimicrobials. 2017 Dec; 16: 1-0.
34. Rasheed NA, Hussein NR. Prevalence of Nasal Carriage Rate and Antimicrobial Susceptibility Testing of *Staphylococcus aureus* Strains Isolated from Syrian Students in Kurdistan, Iraq. Middle East Journal of Rehabilitation and Health Studies. 2020 Jul 31; 7(3).
35. Eticha T, Tamire T, Gelgelu TB. Antibiotic susceptibility pattern of coagulase positive *Staphylococcus aureus* isolated from patients admitted at Tikur Anbessa

- specialized Hospital, Addis Ababa. Health Science Journal. 2022; 16 (2):1-5.
36. Wolde W, Mitiku H, Sarkar R, Shume T. Nasal Carriage Rate of *Staphylococcus aureus*, its associated factors, and antimicrobial susceptibility pattern among health care workers in public hospitals, Harar, Eastern Ethiopia. Infection and Drug Resistance. 2023 Dec 31:3477-86.
37. Gebremeskel FT, Alemayehu T, Ali MM. Methicillin-resistant *Staphylococcus aureus* antibiotic susceptibility profile and associated factors among hospitalized patients at Hawassa University Comprehensive Specialized Hospital, Ethiopia. IJID Regions. 2022 Jun 1; 3: 129-34.
38. Kejela T, Bacha K. Prevalence and antibiotic susceptibility pattern of methicillin-resistant *Staphylococcus aureus* (MRSA) among primary school children and prisoners in Jimma Town, Southwest Ethiopia. Annals of clinical microbiology and antimicrobials. 2013 Jan; 12: 1-1.
39. Humphreys H, Fitzpatrick F, Harvey BJ. Gender differences in rates of carriage and bloodstream infection caused by methicillin-resistant *Staphylococcus aureus*: are they real, do they matter and why? Clinical Infectious Diseases. 2015 Dec 1; 61 (11):1708-14.
40. Mamman GP, Angulu CN, Musa G, Angulu S. Identification and antibiotic susceptibility profile of methicillin and erythromycin resistant genes in clinical and environmental strains of *Staphylococcus aureus* in Minna Nigeria. Bayero Journal of Pure and Applied Sciences. 2022 Dec 9; 15 (1):195-201.
41. Zamanian MH, Shirvani M, Janbakhsh A, Sayad B, Vaziri S, Afshar ZM *et al.*, Antibiotic Resistance in *Staphylococcus aureus* in patients Hospitalized in Imam Reza Hospital of Kermanshah, Iran (2016-2018). Journal of Kermanshah University of Medical Sciences. 2021 Dec 31; 25(4).
42. Hosain Zadegan H, Menati S. The prevalence of methicillin and vancomycin resistant *Staphylococcus aureus* nasal carriage in large teaching hospital personnel. Afr J Microbiol Res. 2011 Oct 16; 5(22):3716-9.
43. Hasanpour AH, Sepidarkish M, Mollalo A, Ardekani A, Almukhtar M, Mechaal A, *et al.* The global prevalence of methicillin-resistant *Staphylococcus aureus* colonization in residents of elderly care canters: a systematic review and meta-analysis. Antimicrobial Resistance & Infection Control. 2023 Jan 29; 12(1):4.
44. Saeed A, Ahsan F, Nawaz M, Iqbal K, Rehman KU, Ijaz T. Incidence of vancomycin resistant phenotype of the methicillin resistant *Staphylococcus aureus* isolated from a

513 tertiary care hospital in Lahore. Antibiotics. 2019 Dec 18; 9(1):3.

514 45. Ghasemian R, Najafi N, Makhloogh A, Khademlou M. Frequency of nasal carriage of  
515 *Staphylococcus aureus* and its antimicrobial resistance pattern in patients on  
516 haemodialysis. 218-221.

517 46. Shibabaw A, Abebe T, Mihret A. Antimicrobial susceptibility pattern of nasal  
518 *Staphylococcus aureus* among Dessie Referral Hospital health care workers, Dessie,  
519 Northeast Ethiopia. International Journal of Infectious Diseases. 2014 Aug 1; 25: 22-  
520 5.

521 47. Osman MM, Osman MM, Mohamed NA, Osman SM, Magzoub M, El-Sanousi SM.  
522 Investigation on vancomycin resistance (VRSA) among methicillin resistant *S. aureus*  
523 (MRSA) in Khartoum State, Sudan. Am J Microbiol Res. 2016 Apr 13; 4(2):56-60.

524 48. Khanal LK, Sah AK, Adhikari RP, Khadka S, Sapkota J, Rai SK. Prevalence and  
525 molecular characterization of methicillin resistant *Staphylococcus aureus* (MRSA)  
526 and vancomycin resistant *Staphylococcus aureus* (VRSA) in a tertiary care hospital.  
527 Nepal Medical College Journal. 2023 Mar 21; 25(1):32-7.